

BEIGENE CONTINUED RAPID GLOBAL GROWTH

Q4 and Full Year 2023 Results

Total Revenues



Product Sales

BRUKINSA[®]

Q4
\$413M

2023
\$1.3B

Tislelizumab

Q4
\$128M

2023
\$537M